Gannex

Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study

Retrieved on: 
Tuesday, November 9, 2021
Phase, Safety, Hong Kong Stock Exchange, PD-L1, American Association, Time, CDC classification system for HIV infection, HIV/AIDS, CHB, Infection, R, Cornerstone, Hepatitis C, HBsAg, CEO, IDE, Gannex, FXR, GBM, RESULTS, Society, AASLD, Nas, Institute of Liver and Biliary Sciences, Liver cancer, Immunotherapy, FASN, PD-1, Association, Liver, OBI Pharma, Inc., PBC, NASH, Degenerative disease, Hepatitis B virus, Late, American Association for Cancer Research, PLUS, Acne, HKEX, Society of Infectious Diseases Pharmacists, THR, Patient, Attention, Medicine in China, Pegasys, Medical device, Pharmaceutical industry, Vaccine

"ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.

Key Points: 
  • "ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.
  • Been selected for oral Late Breaking presentation indicates close attention by the committee of The Liver Meeting 2021 to the study."
  • We are excited to see ASC22 as an immunotherapy play a fundamental role in functional cure of CHB patients.
  • The percentage of patients with baseline HBsAg lower than 500 IU/mL is as high as 30% of all CHB patients.

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

Retrieved on: 
Thursday, February 25, 2021
Melissa Palmer, National Medical Products Administration, Gannex, Nash Motors, FASN, National Music Publishers Association, Cars, Automotive industry, China

The U.S. IND approval enables the Company to initiate the clinical trials in the U.S., the biggest NASH market in the world.

Key Points: 
  • The U.S. IND approval enables the Company to initiate the clinical trials in the U.S., the biggest NASH market in the world.
  • In May 2020, the first IND of ASC41 for NASH indication was approved by China's National Medical Products Administration(NMPA).
  • (Details referring to press release: https://www.ascletis.com/news_detail/175/id/46,2.html )
    Melissa Palmer, MD, Chief Medical Officer of Gannex said, "ASC41 is now the second NASH program we moved into the global development, as Gannex received IND approval and Fast Track Designation for ASC42, an FXR agonist less than 5 months ago.
  • Gannex has an aggressive pipeline development program for NASH with three different targets, FASN, THR- and FXR, and is progressing at full speed with two global development programs and one China focused program. "